Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orthocell Ltd ( (AU:OCC) ) has shared an announcement.
Orthocell Ltd announced a change in the director’s interest, with Michael McNulty acquiring 24,561 ordinary shares through an on-market purchase. This transaction reflects a strategic move by the director to increase his stake in the company, potentially signaling confidence in Orthocell’s future growth and market positioning.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd operates in the biotechnology industry, focusing on regenerative medicine. The company develops and commercializes innovative products for the repair and regeneration of soft tissue injuries, with a market focus on orthopedic and musculoskeletal conditions.
Average Trading Volume: 728,560
Technical Sentiment Signal: Buy
Current Market Cap: A$308.8M
See more insights into OCC stock on TipRanks’ Stock Analysis page.